AGE- AND SEX-RELATED DIFFERENCES IN RESPONSE TO ANALGESIC TREATMENTS IN CHRONIC PAIN PATIENTS: A REAL-WORLD OBSERVATIONAL STUDY
S. Stimolo1, S. Zappalà1, M. Maria2, S. Brundo2, R. Chiaramonte2, E. Buccheri2, S. Caramma2 | 1Università di Padova, Italy; 2Policlinico di Catania, Italy
Abstract
Introduction. Chronic pain is a leading cause of disability, driven by biological, psychological, and sociocultural factors [1, 2]. Evidence highlights significant sex-related differences in pain perception and clinical outcomes following analgesic therapies [1, 3]. This study evaluates the association between biological sex, age, and treatment response in a real-world cohort with moderate-to-severe chronic pain.
Methods. An observational study was conducted at the Pain Management Unit (UOSD Terapia del Dolore) of the Policlinico-San Marco Hospital in Catania. We enrolled 100 patients with chronic pain lasting ≥3 months and moderate-to-severe baseline intensity (NRS > 5). Participants were equally distributed between women (n=50, mean age: 50.4±12.1 years) and men (n=50, mean age: 54.3±13.0 years). Diagnoses included chronic low back pain (n=40; 22 men, 18 women), peripheral neuropathies (n=35; 18 men, 17 women), and fibromyalgia (n=25; 10 men, 15 women). Among patients on stable opioid therapy (n=32), the mean daily dosage was 60 mg morphine equivalents [4]. For subgroup analyses, cohorts were stratified using an age cut-off of 54 years, corresponding to the mean age of the post-menopausal female subgroup (n=28) [3]. Outcomes, assessed at baseline, 1 month, and 3 months, included NRS scores and the Patient Global Impression of Change (PGIC) scale.
Results. At baseline, women reported higher mean NRS scores than men in low back pain (7.8±1.1 vs 7.2±1.0), fibromyalgia (8.1±0.8 vs 7.5±0.9), and peripheral neuropathies (7.4±1.0 vs 7.2±1.2) [1, 3]. After 3 months, men with low back pain showed a significantly greater NRS reduction compared to women (ΔNRS -3.3 vs -2.6; p=0.03). Conversely, in fibromyalgia, clinical improvement was more pronounced in females (ΔNRS -3.2; p<0.01) than in males (ΔNRS -2.2; p=0.07). Achieving a meaningful pain reduction (ΔNRS ≥ 30%) was less frequent in patients aged >54 years compared to younger cohorts (41.4% vs 66.0%; p=0.04) [2]. Among patients on opioids, a PGIC ≥ 5 was observed more frequently in peripheral neuropathies and low back pain than in fibromyalgia, which exhibited the lowest response rates regardless of sex, except for pre-menopausal women treated with tapentadol (50.0%).
Conclusions. Biological sex and chronological age significantly modulate baseline pain intensity and therapeutic responsiveness. Older individuals and patients with nociplastic profiles are less likely to achieve significant pain relief [2]. These data reinforce the need for personalized, gender-specific therapeutic strategies and multidimensional pain management, balancing adverse events with appropriate clinical interventions [1, 4].
Methods. An observational study was conducted at the Pain Management Unit (UOSD Terapia del Dolore) of the Policlinico-San Marco Hospital in Catania. We enrolled 100 patients with chronic pain lasting ≥3 months and moderate-to-severe baseline intensity (NRS > 5). Participants were equally distributed between women (n=50, mean age: 50.4±12.1 years) and men (n=50, mean age: 54.3±13.0 years). Diagnoses included chronic low back pain (n=40; 22 men, 18 women), peripheral neuropathies (n=35; 18 men, 17 women), and fibromyalgia (n=25; 10 men, 15 women). Among patients on stable opioid therapy (n=32), the mean daily dosage was 60 mg morphine equivalents [4]. For subgroup analyses, cohorts were stratified using an age cut-off of 54 years, corresponding to the mean age of the post-menopausal female subgroup (n=28) [3]. Outcomes, assessed at baseline, 1 month, and 3 months, included NRS scores and the Patient Global Impression of Change (PGIC) scale.
Results. At baseline, women reported higher mean NRS scores than men in low back pain (7.8±1.1 vs 7.2±1.0), fibromyalgia (8.1±0.8 vs 7.5±0.9), and peripheral neuropathies (7.4±1.0 vs 7.2±1.2) [1, 3]. After 3 months, men with low back pain showed a significantly greater NRS reduction compared to women (ΔNRS -3.3 vs -2.6; p=0.03). Conversely, in fibromyalgia, clinical improvement was more pronounced in females (ΔNRS -3.2; p<0.01) than in males (ΔNRS -2.2; p=0.07). Achieving a meaningful pain reduction (ΔNRS ≥ 30%) was less frequent in patients aged >54 years compared to younger cohorts (41.4% vs 66.0%; p=0.04) [2]. Among patients on opioids, a PGIC ≥ 5 was observed more frequently in peripheral neuropathies and low back pain than in fibromyalgia, which exhibited the lowest response rates regardless of sex, except for pre-menopausal women treated with tapentadol (50.0%).
Conclusions. Biological sex and chronological age significantly modulate baseline pain intensity and therapeutic responsiveness. Older individuals and patients with nociplastic profiles are less likely to achieve significant pain relief [2]. These data reinforce the need for personalized, gender-specific therapeutic strategies and multidimensional pain management, balancing adverse events with appropriate clinical interventions [1, 4].
References
- 1. Marchesini et al., 2025 (Gender Task Force): Added to Introduction (sex-related differences), Results (greater baseline pain in women), and Conclusions (gender-specific medicine).
- 2. Dagnino & Campos, 2022 (Elderly): Supporting the data on the age cutoff, the lower response in older adults (>54 years, ΔNRS ≥ 30%), and nociplastic/aging pain.
- 3. Stieger et al., 2025 (Hormonal Variations): Added to Methods to biologically justify the 54-year cutoff based on postmenopause, and to Clinical Results.
- 4. Caramma et al., 2026 (Opioids Catania): Added to Methods (for morphine mg equivalents and opioid management) and Conclusions (need to address adverse effects).
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.